Study on Durvalumab, Bevacizumab, and TACE for Advanced Hepatocellular Carcinoma
A clinical trial is evaluating the combination of durvalumab, bevacizumab, and TACE for advanced HCC, focusing on 6-month progression-free survival.
Asset / Drug
Drug and asset intelligence for Durvalumab with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Immunotherapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.